Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 5/2017

01.07.2017 | Clinical Investigation

Heterozygous deletion of the OPA1 gene in patients with dominant optic atrophy

verfasst von: Takaaki Hayashi, Hiroyuki Sasano, Satoshi Katagiri, Kazushige Tsunoda, Shuhei Kameya, Mitsuru Nakazawa, Takeshi Iwata, Hiroshi Tsuneoka

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several OPA1 variants cause dominant optic atrophy (DOA), the most common hereditary optic atrophy. Here, we describe a newly discovered OPA1 deletion in 3 patients with DOA.

Methods

A female proband, her brother, and her mother underwent complete ophthalmologic examinations that included optical coherence tomography and visual field assessments using a Humphrey Field Analyzer with both standard automated perimetry (SAP) and short-wavelength automated perimetry (SWAP). Genomic DNA from each patient was examined to detect genomic rearrangements involving OPA1; the genetic analysis involved both multiplex ligation probe amplification and conventional Sanger sequencing.

Results

Each patient had temporal optic disc pallor and significant thinning of the retinal nerve fiber layer in both eyes, although there was phenotypic variability among the patients that ranged from asymptomatic to moderately decreased visual acuity. For the affected brother and mother, the mean deviation values from SAP were within the normal range, whereas those from SWAP were significantly below the normal range (P < .05). The genetic analysis identified a newly discovered heterozygous deletion that encompasses exons 9–14 and revealed a breakpoint junction that directly connects intron 8 to intron 14.

Conclusions

This newly described deletion is likely to lead to loss of function in the functionally important GTPase domain encoded by exons 9–16, and the heterozygosity suggested that haploinsufficiency caused the phenotypes. The deletion may be associated with mild DOA phenotypes ranging from asymptomatic to moderately decreased visual acuity.
Literatur
2.
Zurück zum Zitat Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211–5.CrossRefPubMed Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211–5.CrossRefPubMed
3.
Zurück zum Zitat Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207–10.CrossRefPubMed Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet. 2000;26:207–10.CrossRefPubMed
4.
Zurück zum Zitat Shimizu S, Mori N, Kishi M, Sugata H, Tsuda A, Kubota N. A novel mutation of the OPA1 gene in a Japanese family with optic atrophy type 1. Jpn J Ophthalmol. 2002;46:336–40.CrossRefPubMed Shimizu S, Mori N, Kishi M, Sugata H, Tsuda A, Kubota N. A novel mutation of the OPA1 gene in a Japanese family with optic atrophy type 1. Jpn J Ophthalmol. 2002;46:336–40.CrossRefPubMed
5.
Zurück zum Zitat Hayashi T, Gekka T, Omoto S, Takeuchi T, Kitahara K. Dominant optic atrophy caused by a novel OPA1 splice site mutation (IVS20+ 1G–> A) associated with intron retention. Ophthalmic Res. 2005;37:214–24.CrossRefPubMed Hayashi T, Gekka T, Omoto S, Takeuchi T, Kitahara K. Dominant optic atrophy caused by a novel OPA1 splice site mutation (IVS20+ 1G–> A) associated with intron retention. Ophthalmic Res. 2005;37:214–24.CrossRefPubMed
6.
Zurück zum Zitat Nakamura M, Lin J, Ueno S, Asaoka R, Hirai T, Hotta Y, et al. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy. Ophthalmology. 2006;113(483–8):e1. Nakamura M, Lin J, Ueno S, Asaoka R, Hirai T, Hotta Y, et al. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy. Ophthalmology. 2006;113(483–8):e1.
7.
Zurück zum Zitat Ferre M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P. eOPA1: an online database for OPA1 mutations. Hum Mutat. 2005;25:423–8.CrossRefPubMed Ferre M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P. eOPA1: an online database for OPA1 mutations. Hum Mutat. 2005;25:423–8.CrossRefPubMed
8.
Zurück zum Zitat Ferre M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, et al. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat. 2009;30:e692–705.CrossRefPubMed Ferre M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, et al. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat. 2009;30:e692–705.CrossRefPubMed
9.
Zurück zum Zitat Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, et al. Mutation spectrum and splicing variants in the OPA1 gene. Hum Genet. 2001;109:584–91.CrossRefPubMed Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, et al. Mutation spectrum and splicing variants in the OPA1 gene. Hum Genet. 2001;109:584–91.CrossRefPubMed
10.
Zurück zum Zitat Toomes C, Marchbank NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, et al. Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. Hum Mol Genet. 2001;10:1369–78.CrossRefPubMed Toomes C, Marchbank NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, et al. Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. Hum Mol Genet. 2001;10:1369–78.CrossRefPubMed
11.
Zurück zum Zitat Pesch UE, Leo-Kottler B, Mayer S, Jurklies B, Kellner U, Apfelstedt-Sylla E, et al. OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance. Hum Mol Genet. 2001;10:1359–68.CrossRefPubMed Pesch UE, Leo-Kottler B, Mayer S, Jurklies B, Kellner U, Apfelstedt-Sylla E, et al. OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance. Hum Mol Genet. 2001;10:1359–68.CrossRefPubMed
12.
Zurück zum Zitat Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, et al. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2002;43:1715–24.PubMed Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, et al. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2002;43:1715–24.PubMed
13.
Zurück zum Zitat Baris O, Delettre C, Amati-Bonneau P, Surget MO, Charlin JF, Catier A, et al. Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy. Hum Mutat. 2003;21:656.CrossRefPubMed Baris O, Delettre C, Amati-Bonneau P, Surget MO, Charlin JF, Catier A, et al. Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy. Hum Mutat. 2003;21:656.CrossRefPubMed
14.
Zurück zum Zitat Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010;117:1538–46 (46.e1).CrossRefPubMedPubMedCentral Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010;117:1538–46 (46.e1).CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Marchbank NJ, Craig JE, Leek JP, Toohey M, Churchill AJ, Markham AF, et al. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet. 2002;39:e47.CrossRefPubMedPubMedCentral Marchbank NJ, Craig JE, Leek JP, Toohey M, Churchill AJ, Markham AF, et al. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet. 2002;39:e47.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Fuhrmann N, Alavi MV, Bitoun P, Woernle S, Auburger G, Leo-Kottler B, et al. Genomic rearrangements in OPA1 are frequent in patients with autosomal dominant optic atrophy. J Med Genet. 2009;46:136–44.CrossRefPubMed Fuhrmann N, Alavi MV, Bitoun P, Woernle S, Auburger G, Leo-Kottler B, et al. Genomic rearrangements in OPA1 are frequent in patients with autosomal dominant optic atrophy. J Med Genet. 2009;46:136–44.CrossRefPubMed
17.
Zurück zum Zitat Almind GJ, Gronskov K, Milea D, Larsen M, Brondum-Nielsen K, Ek J. Genomic deletions in OPA1 in Danish patients with autosomal dominant optic atrophy. BMC Med Genet. 2011;12:49.CrossRefPubMedPubMedCentral Almind GJ, Gronskov K, Milea D, Larsen M, Brondum-Nielsen K, Ek J. Genomic deletions in OPA1 in Danish patients with autosomal dominant optic atrophy. BMC Med Genet. 2011;12:49.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Walters JW, Gaume A, Pate L. Short wavelength-automated perimetry compared with standard achromatic perimetry in autosomal dominant optic atrophy. Br J Ophthalmol. 2006;90:1267–70.CrossRefPubMedPubMedCentral Walters JW, Gaume A, Pate L. Short wavelength-automated perimetry compared with standard achromatic perimetry in autosomal dominant optic atrophy. Br J Ophthalmol. 2006;90:1267–70.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Newman NJ, Biousse V. Hereditary optic neuropathies. Eye (Lond). 2004;18:1144–60.CrossRef Newman NJ, Biousse V. Hereditary optic neuropathies. Eye (Lond). 2004;18:1144–60.CrossRef
20.
Zurück zum Zitat Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies: disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81–114.CrossRefPubMedPubMedCentral Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies: disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81–114.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Barboni P, Savini G, Cascavilla ML, Caporali L, Milesi J, Borrelli E, et al. Early macular retinal ganglion cell loss in dominant optic atrophy: genotype–phenotype correlation. Am J Ophthalmol. 2014;158(628–36):e3. Barboni P, Savini G, Cascavilla ML, Caporali L, Milesi J, Borrelli E, et al. Early macular retinal ganglion cell loss in dominant optic atrophy: genotype–phenotype correlation. Am J Ophthalmol. 2014;158(628–36):e3.
22.
Zurück zum Zitat Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131:338–51.CrossRefPubMed Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131:338–51.CrossRefPubMed
23.
Zurück zum Zitat Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771–86.CrossRefPubMedPubMedCentral Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771–86.CrossRefPubMedPubMedCentral
Metadaten
Titel
Heterozygous deletion of the OPA1 gene in patients with dominant optic atrophy
verfasst von
Takaaki Hayashi
Hiroyuki Sasano
Satoshi Katagiri
Kazushige Tsunoda
Shuhei Kameya
Mitsuru Nakazawa
Takeshi Iwata
Hiroshi Tsuneoka
Publikationsdatum
01.07.2017
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 5/2017
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-017-0522-0

Weitere Artikel der Ausgabe 5/2017

Japanese Journal of Ophthalmology 5/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.